CAPRCAPRICOR THERAPEUTICS, INC.

Nasdaq capricor.com


$ 5.31 $ 0.10 (1.92 %)    

Thursday, 13-Jun-2024 12:46:24 EDT
QQQ $ 474.79 $ -2.79 (-0.58 %)
DIA $ 385.43 $ -1.45 (-0.37 %)
SPY $ 540.27 $ -2.84 (-0.52 %)
TLT $ 93.54 $ 0.34 (0.36 %)
GLD $ 212.46 $ -1.97 (-0.92 %)
$ 5.06
$ 5.21
$ 5.27 x 100
$ 0.00 x 0
$ 5.21 - $ 5.41
$ 2.68 - $ 8.22
638,765
na
158.65M
$ 0.73
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-11-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-17-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-11-2022 12-31-2021 10-K
11 11-11-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-15-2021 12-31-2020 10-K
15 11-13-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-15-2020 03-31-2020 10-Q
18 03-27-2020 12-31-2019 10-K
19 11-08-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-14-2019 03-31-2019 10-Q
22 03-29-2019 12-31-2018 10-K
23 11-14-2018 09-30-2018 10-Q
24 08-13-2018 06-30-2018 10-Q
25 05-14-2018 03-31-2018 10-Q
26 03-22-2018 12-31-2017 10-K
27 11-14-2017 09-30-2017 10-Q
28 08-14-2017 06-30-2017 10-Q
29 05-15-2017 03-31-2017 10-Q
30 03-16-2017 12-31-2016 10-K
31 11-14-2016 09-30-2016 10-Q
32 08-15-2016 06-30-2016 10-Q
33 05-13-2016 03-31-2016 10-Q
34 03-30-2016 12-31-2015 10-K
35 11-13-2015 09-30-2015 10-Q
36 08-14-2015 06-30-2015 10-Q
37 05-13-2015 03-31-2015 10-Q
38 03-16-2015 12-31-2014 10-K
39 11-14-2014 09-30-2014 10-Q
40 08-14-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 whats-going-on-with-capricor-therapeutics-stock-tuesday

Capricor Therapeutics announced successful completion of a Type-B meeting with the U.S. Food and Drug Administration (FDA).

 capricor-therapeutics-completes-type-b-meeting-with-fda-for-cap-1002-program-for-duchenne-muscular-dystrophy-with-aim-to-expedite-bla-pathway

--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results--

 whats-going-on-with-capricor-therapeutics-stock-tuesday

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is trading higher Tuesday after the company announced three-year results from the on...

 capricor-therapeutics-reports-3-year-efficacy-results-from-hope-2-open-label-extension-study-of-cap-1002-in-dmd

--Results in Performance of the Upper Limb (PUL 2.0) Continue to Show Benefits in Skeletal Muscle Function After 3 Years of CAP...

 oppenheimer-initiates-coverage-on-capricor-therapeutics-with-outperform-rating-announces-price-target-of-14

Oppenheimer analyst Leland Gershell initiates coverage on Capricor Therapeutics (NASDAQ:CAPR) with a Outperform rating and a...

 ladenburg-thalmann-maintains-buy-on-capricor-therapeutics-raises-price-target-to-25

Ladenburg Thalmann analyst Aydin Huseynov maintains Capricor Therapeutics (NASDAQ:CAPR) with a Buy and raises the price targ...

 cantor-fitzgerald-reiterates-overweight-on-capricor-therapeutics-maintains-8-price-target

Cantor Fitzgerald analyst Kristen Kluska reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Overweight and maintains $8 p...

 hc-wainwright--co-reiterates-buy-on-capricor-therapeutics-maintains-40-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40...

 capricor-therapeutics-q1-2024-gaap-eps-031-misses-011-estimate-sales-4906m-miss-9700m-estimate

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate ...

 capricor-therapeutics-to-present-exosome-platform-updates-at-asgct-27th-annual-meeting-preclinical-findings-show-exosome-based-therapeutic-approach-for-the-treatment-of-arginase-1-deficiency

-Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)- -Presentatio...

 hc-wainwright--co-reiterates-buy-on-capricor-therapeutics-maintains-40-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40...

 hc-wainwright--co-reiterates-buy-on-capricor-therapeutics-maintains-40-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40...

 capricor-therapeutics-q4-2023-gaap-eps-0020-beats-0200-estimate-sales-12088m-beat-10600m-estimate

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.020) per share which beat the analyst consensus estimate o...

 earnings-scheduled-for-february-29-2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...